サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1435073

アミロイドーシス治療薬市場：タイプ別、エンドユーザー別-2024-2030年の世界予測

Amyloidosis Treatment Market by Type (Medication, Surgery), End-Users (Hospitals, Specialty Centers) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 188 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
アミロイドーシス治療薬市場：タイプ別、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 188 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アミロイドーシス治療薬市場規模は2023年に52億3,000万米ドルと推計され、2024年には57億米ドルに達し、CAGR 7.57%で2030年には87億3,000万米ドルに達すると予測されます。

アミロイドーシス治療薬の世界市場

主な市場の統計
基準年[2023］ 52億3,000万米ドル
予測年[2024］ 57億米ドル
予測年 [2030] 87億3,000万米ドル
CAGR（%） 7.57%
アミロイドーシス治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはアミロイドーシス治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、アミロイドーシス治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-アミロイドーシス治療薬市場の市場規模および予測は？

2-アミロイドーシス治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-アミロイドーシス治療薬市場における技術動向と規制の枠組みは？

4-アミロイドーシス治療薬市場における主要ベンダーの市場シェアは？

5-アミロイドーシス治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 増加する巨大人口におけるアミロイドーシスの有意な有病率
      • 早期診断とアミロイドーシス治療に対する意識の高まり
      • 新規アミロイドーシス治療薬の開発に向けた強力な調査活動
    • 抑制要因
      • アミロイドーシス治療の高額な費用と償還政策に関連する問題
    • 機会
      • アミロイドーシス治療のための新しい治療選択肢の出現
      • 近代化されたヘルスケアインフラを開発するための投資の増加
    • 課題
      • アミロイドーシス治療に伴う複雑さとリスク
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 アミロイドーシス治療薬市場：タイプ別

  • 薬
    • 化学療法
    • 標的療法
      • 抗血管新生療法
      • モノクローナル抗体
      • プロテアソーム阻害剤
  • 手術
    • 骨髄移植・幹細胞移植
    • 臓器移植

第7章 アミロイドーシス治療薬市場：エンドユーザー別

  • 病院
  • 専門センター

第8章 南北アメリカのアミロイドーシス治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域のアミロイドーシス治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカのアミロイドーシス治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbvie, Inc.
    • Acrotech Biopharma, Inc
    • Alexion Pharmaceuticals
    • Alnylam Pharmaceuticals Inc.
    • Arcturus Therapeutics, Inc.
    • Astellas Pharma, Inc.
    • AstraZeneca PLC
    • Attralus, Inc.
    • BridgeBio Pharma, Inc.
    • Bristol-Myers Squibb Company
    • Corino Therapeutics, Inc.
    • GlaxoSmithKline PLC
    • Ionis Pharmaceuticals, Inc.
    • Johnson & Johnson Services Inc
    • Merck & Co., Inc.
    • Neurimmune AG
    • Oncopeptides AB
    • Pfizer Inc.
    • Proclara Biosciences Inc.
    • Prothena Corporation PLC
    • Regeneron Pharmaceuticals Inc.
    • SOM INNOVATION BIOTECH, SA,
    • Sorrento Therapeutics, Inc.
    • Spectrum Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. AMYLOIDOSIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. AMYLOIDOSIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AMYLOIDOSIS TREATMENT MARKET DYNAMICS
  • FIGURE 7. AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 10. AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. AMYLOIDOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. AMYLOIDOSIS TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 11. AMYLOIDOSIS TREATMENT MARKET SIZE, BY ANTI-ANGIOGENESIS THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 16. AMYLOIDOSIS TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANTATION/STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 19. AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 150. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 160. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 170. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 175. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 180. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 190. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 200. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 205. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 210. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 215. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 220. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 230. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 231. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 232. AMYLOIDOSIS TREATMENT MARKET LICENSE & PRICING
目次
Product Code: MRR-C002B1C9971D

[188 Pages Report] The Amyloidosis Treatment Market size was estimated at USD 5.23 billion in 2023 and expected to reach USD 5.70 billion in 2024, at a CAGR 7.57% to reach USD 8.73 billion by 2030.

Global Amyloidosis Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 5.23 billion
Estimated Year [2024] USD 5.70 billion
Forecast Year [2030] USD 8.73 billion
CAGR (%) 7.57%
Amyloidosis Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Amyloidosis Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Amyloidosis Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Amyloidosis Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Acrotech Biopharma, Inc, Alexion Pharmaceuticals, Alnylam Pharmaceuticals Inc., Arcturus Therapeutics, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Attralus, Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Corino Therapeutics, Inc., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., Johnson & Johnson Services Inc, Merck & Co., Inc., Neurimmune AG, Oncopeptides AB, Pfizer Inc., Proclara Biosciences Inc., Prothena Corporation PLC, Regeneron Pharmaceuticals Inc., SOM INNOVATION BIOTECH, SA,, Sorrento Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Amyloidosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Medication
      • Chemotherapy
      • Targeted therapy
        • Anti-Angiogenesis Therapy
        • Monoclonal Antibodies
        • Proteasome Inhibitors
    • Surgery
      • Bone Marrow Transplantation/Stem Cell Transplantation
      • Organ Transplantation
  • End-Users
    • Hospitals
    • Specialty Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Amyloidosis Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Amyloidosis Treatment Market?

3. What are the technology trends and regulatory frameworks in the Amyloidosis Treatment Market?

4. What is the market share of the leading vendors in the Amyloidosis Treatment Market?

5. Which modes and strategic moves are suitable for entering the Amyloidosis Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Amyloidosis Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant prevalence of amyloidosis among rising gigantic population
      • 5.1.1.2. Growing awareness about early diagnosis and amyloidosis treatments
      • 5.1.1.3. Robust research activities to develop novel amyloidosis drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Issues related to high cost and reimbursement policies of amyloidosis treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of new treatment options for treating amyloidosis
      • 5.1.3.2. Rising investments to develop modernized healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities and risk associated with amyloidosis treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Amyloidosis Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Medication
    • 6.3.1. Chemotherapy
    • 6.3.2. Targeted therapy
      • 6.3.3.1. Anti-Angiogenesis Therapy
      • 6.3.3.2. Monoclonal Antibodies
      • 6.3.3.3. Proteasome Inhibitors
  • 6.3. Surgery
    • 6.4.1. Bone Marrow Transplantation/Stem Cell Transplantation
    • 6.4.2. Organ Transplantation

7. Amyloidosis Treatment Market, by End-Users

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Specialty Centers

8. Americas Amyloidosis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Amyloidosis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Amyloidosis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbvie, Inc.
    • 12.1.2. Acrotech Biopharma, Inc
    • 12.1.3. Alexion Pharmaceuticals
    • 12.1.4. Alnylam Pharmaceuticals Inc.
    • 12.1.5. Arcturus Therapeutics, Inc.
    • 12.1.6. Astellas Pharma, Inc.
    • 12.1.7. AstraZeneca PLC
    • 12.1.8. Attralus, Inc.
    • 12.1.9. BridgeBio Pharma, Inc.
    • 12.1.10. Bristol-Myers Squibb Company
    • 12.1.11. Corino Therapeutics, Inc.
    • 12.1.12. GlaxoSmithKline PLC
    • 12.1.13. Ionis Pharmaceuticals, Inc.
    • 12.1.14. Johnson & Johnson Services Inc
    • 12.1.15. Merck & Co., Inc.
    • 12.1.16. Neurimmune AG
    • 12.1.17. Oncopeptides AB
    • 12.1.18. Pfizer Inc.
    • 12.1.19. Proclara Biosciences Inc.
    • 12.1.20. Prothena Corporation PLC
    • 12.1.21. Regeneron Pharmaceuticals Inc.
    • 12.1.22. SOM INNOVATION BIOTECH, SA,
    • 12.1.23. Sorrento Therapeutics, Inc.
    • 12.1.24. Spectrum Pharmaceuticals, Inc.
    • 12.1.25. Takeda Pharmaceutical Company Limited
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing